Table 2.
Effects of Δ9-tetrahydrocannabinol/cannabidiol (THC/CBD) combination on locomotor activity.
| Species | THC | CBD | Locomotor Activity | Reference |
|---|---|---|---|---|
| Rat | Single i.p. 10–30 mg/kg | Simultaneous single i.p. CBD 10–30 mg/kg with THC; i.p. CBD 10–30 mg/kg or 30–90 mg/kg, 30 min prior to THC | No effect on hypolocomotion induced by THC | [61] |
| Mouse | Single i.p. THC (0, 1.8, 3.2, 5.6 or 10 mg/kg) | Single i.p. CBD (30 mg/kg) 15 min before THC | CBD enhanced hypolocomotion induced by low to moderate THC doses | [63] |
| Single i.p. THC 1.8 mg/kg | Single i.p. CBD (0, 10 or 30 mg/kg) 13 h or 15 min before THC |
CBD did not change significantly THC effects on locomotor activity. | ||
| Rat | Vaporized THC (12.5, 25, 50, 100, 200 mg/mL) 0.125 mL in a 40 min session |
CBD (100, 400 mg/mL) 0.125 mL in a 40 min session | CBD alone when inhaled suppressed locomotor activity. THC and THC/CBD (1:4) inhalation decreased total locomotion in the center of the OF. |
[64] |
| Monkey | Increasing i.m. THC dose (0.1–1 mg/kg for four months | Increasing i.m. CBD dose (0.3–3 mg/kg) for four months | Tolerance to hypolocomotion induced by THC appeared after weeks. CBD did not influence THC hypolocomotion or occurrence of tolerance. | [65] |
| Mouse | Single i.p. THC (10 mg/kg) |
Simultaneous i.p. CBD (20 mg/kg) |
CBD did not modify hypolocomotion induced by THC. | [67] |
| Mouse | Single i.p. THC (10 mg/kg) |
Simultaneous single i.p. CBD (10 mg/kg) |
CBD enhanced hypolocomotion induced by THC. | [68] |
i.p. = intraperitoneal; i.m. = intramuscular.